Dr Lekshmi R. Nath joined as Assistant Professor in the Department of Pharmacognosy at Amrita School of Pharmacy in January 2018. She pursued her PhD under Dr Ruby John Anto, Cancer Research Program, Rajiv Gandhi Centre for Biotechnology (RGCB), an autonomous Research Institution under DBT, Trivandrum, Kerala. Her PhD findings on hepatocellular carcinoma recently received both US and Canadian Patent ( WO 2017208254 A1, “Uttroside B And Derivatives Thereof As Therapeutics For Hepatocellular Carcinoma”. The FDA has recently granted an orphan drug designation to the small molecule chemotherapeutic uttroside-B for use as a treatment in patients with hepatocellular carcinoma. Q BioMed, a biopharmaceutical company has already started a clinical trial for uttroside B against Hepatocellular carcinoma (https://adisinsight.springer.com/drugs/800048876). BioMed, Rajiv Gandhi Centre for Biotechnology and Oklahoma Medical Research Foundation enter research collaboration to develop Uttroside B against liver cancer. She completed her M.Pharm. from KLE University's College of Pharmacy, Karnataka (Formerly known as KLES College of Pharmacy) and B.Pharm from Dept of Pharmaceutical Sciences, MG University, Kottayam. She is having 9 years of research experience at RGCB and has published several publications in many renowned International Journals including Scientific Reports, Plose ONE, RSC Advance, Frontiers in Microbiology etc. Her research interest includes the study of signalling events asso